Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: June 2013

Section 3 - Roles of the multidisciplinary team

References

1. MorrisM, MartinC, SchenkmanM. Striding out with Parkinson disease: evidence-based physical therapy for gait disorders. Phys Ther 2010;90:280–8.
2. RochesterL, NieuwboerA, LordS. Physiotherapy for Parkinson’s disease: defining evidence within a framework for intervention. Neurodegen Disease Management 2011;1:57–65.
3. KeusS, BloemB, HendriksE, Bredero-CohenA, MunnekeM. Evidence-based analysis of physical therapy in Parkinson’s disease with recommendations for practice and research. Mov Disord 2007;22:451–60.
4. QuinnL, BusseM, DawesM, et al. European Huntington’s Disease Network Physiotherapy Guidance Document 2009. See http://www.huntingtonswa.org.au/resources/physiotherapy-guidance-doc-2009.pdf.
5. RamaswarmyB, JonesD, GoodwinV, et al. Quick reference cards (UK) and guidance notes for physiotherapists working with people with Parkinson’s disease. London: Parkinson’s Disease Society, 2009.
6. NieuwboerA, RochesterL, JonesD. Cueing gait and gait-related mobility in peoples with Parkinson’s disease: developing a therapeutic method based on the international classification of functioning, disability, and health. Topics Geriatric Rehabil. 2008;24:151–65.
7. BilneyB, MorrisM, PerryA. Effectiveness of physiotherapy, occupational therapy and speech pathology for people with Huntington’s disease: a systematic review. Neurorehabil Neural Repair. 2003;17:12–24.
8. DibbleL, AddisonO, PapaE. The effects of exercise on balance in persons with Parkinson’s diease: a systematic review across the disease spectrum. J Neurol Phys Ther 2009;33:14–26.
9. FalvoM, SchillingB, EarhartG. Parkinson’s disease and resistive exercise: rationale, review, and recommendations. Mov Disord 2008;23:1–11.
10. GoodwinV, RichardsS, TaylorR, TaylorA, CampbellJ. The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2008;23:631–40.
11. BilneyB, MorrisM, DenisenkoS. Physiotherapy for people with movement disorders arising from basal ganglia dysfunction. New Zealand J Physiotherapy. 2003;31:94–100.
12. AllcockLM, RowanEN, SteenIN, et al. Impaired attention predicts falling in Parkinson’s disease. Parkinsonism Relat Disord 2009;15:110–15.
13. KeusS, MunnekeM, NijkrakeM, KwakkelG, BloemB. Physical therapy in Parkinson’s disease: evolution and future challenges. Mov Disord 2009;24:1–14.
14. World Health Organisation. International Classification of Functioning, Disability, and Health. WHO: Geneva, 2001.
15. LordS, RochesterL, HetheringtonV, AllcockLM, BurnD. Executive dysfunction and attention contribute to gait interference in ‘off’ state Parkinson’s disease. Gait Posture 2010;31:169–74.
16. World Health Organisation ICF, Research Branch. ICF Core Set Projects. 2010. See http://www.icf-research-branch.org/icf-core-sets-projects.html.
17. BurnD, RowanE, AllanL, et al. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006;77:585–9.
18. AdkinsD, BoychukJ, RempleM, KleimJ. Motor training induces experience-specific patterns of plasticity across motor cortex and spinal cord. J Appl Physiol 2006;101:1776–82.
19. PetzingerG, FisherB, Van LeeuwenJ-E, et al. Enhancing neuroplasticity in the basal ganglia: the role of exercise in Parkinson’s disease. Mov Disord 2010;25:S141–S5.
20. SutooD, AkiyamaK. Regulation of brain function by exercise. Neurobiol Disease. 2003;13:1–14.
21. TaylorN, PizzariT. Therapeutic exercise guidelines for the rehabilitation of older people following fracture. In: MorrisM, SchooA, eds. Optimising Exercise And Physical Activity in Older People. Edinburgh: Butterworth-Heinemann, 2004.
22. QuinnL, BusseM, KhalilH, et al. Client and therapist views on exercise programmes for early–mid stage Parkinson’s disease and Huntington’s disease. Disabil Rehabil 2010;32:917–28.
23. NieuwboerA, KwakkelG, RochesterL, et al. Cueing training in the home improves gait-related mobility in Parkinson’s disease: the RESCUE trial. J Neurol Neurosurg Psychiatr 2007;78:134–40.
24. CunningtonR, IansekR, BradshawJ. Movement-related potentials in Parkinson’s disease: external cues and attentional strategies. Mov Disord 1999;14:63–8.
25. DebaereF, WenderothN, SunaertS, Van HeckeP, SwinnenS. Internal vs external generation of movements: differential neural pathways involved in bimanual coordination performed in the presence or absence of augmented visual feedback. NeuroImage 2003;19:764–76.
26. RochesterL, BakerK, HetheringtonV, et al. Evidence for motor learning in Parkinson’s disease: acquisition, automaticity and retention of cued gait performance after training with external rhythmical cues. Brain Res 2010;1319C:103–11.
27. MorrisM, IansekR, McGinleyJ, MatyasT, HuxhamF. Three-dimensional gait biomechanics in Parkinson’s disease: evidence for a centrally mediated amplitude regulation disorder. Mov Disord 2005;20:40–50.
28. RochesterL, BakerK, NieuwboerA, BurnD. Targeting dopa sensitive and dopa resistant gait dysfunction in PD: selective responses to internal and external cues. Mov Disord 2011;26:430–5.
29. HausdorffJ, SchaafsmaJ, BalashY, et al. Impaired regulation of stride variability in Parkinson’s disease subjects with freezing of gait. Exp Brain Res 2003;149:187–94.
30. MorrisM, IansekR, MatyasT, SummersJ. Stride length regulation in Parkinson’s disease: normalisation strategies and underlying mechanisms. Brain 1996;119:551–68.
31. DibbleL, HaleT, MarcusR, et al. High-intensity resistance training amplifies muscle hypertrophy and functional gains in persons with Parkinson’s disease. Mov Disord 2006;21:1444–52.
32. DibbleL, HaleT, MarcusR, GerberJ, LaStayoP. High intensity eccentric resistance training decreases bradykinesia and improves quality of life in persons with Parkinson’s disease: a preliminary study. Parkinsonism Relat Dis 2009;15:752–7.
33. HermanT, GiladiN, HausdorffJ. Treadmill training for the treatment of gait disturbances in people with Parkinson’s disease: a mini-review. J Neural Transmission 2009;116:307–18.
34. MehrholzJ, FriisR, KuglerJ, et al. Treadmill training for peoples with Parkinson’s disease. Cochrane Databse Syst Rev 2010;20:CD007830.
35. SteffenT, BoeveB, Mollinger-ReimannL. Long-term locomotor training for gait and balance in a people with mixed progressive supranuclear palsy and corticobasal degeneration. Phys Ther 2007;87:1078–87.
36. SuteerawattananonM, MacNeillB, ProtasE. Supported treadmill training for gait and balance in a people with progressive supranuclear palsy. Phys Ther 2002;82:485–95.
37. MorrisM, IansekR, KirkwoodB. A randomized controlled trial of movement strategies compared with exercise for people with Parkinson’s disease. Mov Disord 2009;24:64–71.
38. FrazzittaG, MaestriR, UccelliniD, BertottiG, AbelliP. Rehabilitation treatment of gait in peoples with Parkinson’s disease with freezing: a comparison between two physical therapy protocols using visual and auditory cues with or without treadmill training. Mov Disord 2009;24:1139–43.
39. AshburnA, StackE, BallingerC, FazakarleyL, FittonC. The circumstances of falls among people with Parkinson’s disease and the use of falls diaries to facilitate reporting. Disability Rehabil 2008;30:1205–12.
40. LamontRM, MorrisME, WoollacottMH, BrauerSG. Parkinsons Dis 2012;2012:856237.
41. AllenN, CSherringtonC, PaulS, CanningCG. Balance and falls in Parkinson’s diease: a meta-analysis of the effects of exercise and motor training. Mov Disord 2011;26:1605–15.
42. WedgeF. The impact of resistance training on balance and functional ability of a peoples with multiple system atrophy. J Geriatric Phys Ther 2008;31:79–83.
43. SmaniaN, CoratoE, TinazziM, et al. Effect of balance training on postural instability in patients with idiopathic Parkinson’s disease. Neurorehab Neural Repair 2010;24:826–34.
44. PickeringRM, GrimbergenYA, RigneyU, et al. A meta-analysis of six prospective studies of falling in Parkinson’s disease. Mov Disord 2007;22:1892–900.
45. GrimbergenYA, KnolM, BloemBR, et al. Falls and gait disturbance in Huntington’s disease. Mov Disord 2008;23:970–6.
46. BusseM, WilesC, RosserA. Mobility and falls in people with Huntington’s disease. J Neurol Neurosurg Psychiatry 2009;80:88–90.
47. GalnaB, MurphyAT, MorrisME. Obstacle crossing in people with Parkinson’s disease: foot clearance and spatiotemporal deficits. Human Mov Sci 2010;29:843–52.
48. LattM, LordS, MorrisJ, FungV. Clinical and physiological assessments for elucidating falls risk in Parkinson’s disease. Mov Disord 2009;24:1280–9.
49. KerrG, Worringham, CJ, Cole, MH, Lacherez, PF, Wood, JM, Silburn, PA. Predictors of future falls in Parkinson disease. Neurology 2010;75:116–24.
50. ProudEL, Morris, ME. Skilled hand dexterity in Parkinson’s disease: effects of adding a concurrent task. Arch Phys Med Rehabil 2010;91:794–9.
51. WadeD. Measurement in Neurological Rehabilitation. Oxford: Oxford University Press, 1992.
52. Huntington Study Group. Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136–42.
53. FahnS, EltonR, Committee obotMDTF, eds. Unified Parkinson’s Disease Rating Scale. New York: Macmillan, 1987.
54. PodsiadloD, RicharsonS. The time ‘Up & Go’: a test of basic functional mobiltiy for frail elderly persons. J Am Geriatric Soc 1991;39:142–8.
55. GoetzC, TilleyB, ShaftmanS, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129–70.
56. PowellL, MyersA. The Activities-specific Balance Confidence (ABC) scale. J Gerontology 1995;50A:M28–M34.
57. TinettiM. Performance-oriented assessment of mobility problems in elderly peoples. J Am Geriatric Soc 1986;34(2):119–26.
58. NieuwboerA, RochesterL, HermanT, et al. Reliability of the new freezing of gait questionnaire: agreement between peoples with Parkinson’s disease and their carers. Gait Posture 2009;30:459–63.
59. NieuwboerA, De WeerdtW, DomR, BogaertsK, GodelieveN. Development of an activity scale for individuals with advanced Parkinson’s disease: reliability and ‘on–off’ variability. Phys Ther 2000;11:1087–96.
60. EnrightP, SherrillD. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998;158:1384–7.
61. Department of Health. The General Practice Physical Activity Questionnaire. 2006. In: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_063812.
62. Health Do. The General Practice Activity Questionnaire. London: The Department of Health, 2006. See http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_063812.
63. PetoV, JenkinsonC, FitzpatrickR. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 1995;4:241–8.
64. SohSE, McGinleyJL, WattsJJ, IansekR, MorrisME. Rural living and health related quality of life in Australians with Parkinson’s disease. Rural Remote Health 2012;12:2158.
65. SohSE, McGinleyJL, WattsJJ, et al. Determinants of health-related quality of life in people with Parkinson’s disease: a path analysis. Qual Life Res 2012;Oct 16 [Epub ahead of print].
66. KellyDH, McGinleyJL, HuxhamFE, et al. Health-related quality of life and strain in caregivers of Australians with Parkinson’s disease: an observational study. BMC Neurol 2012;12:57.
67. WareJ, SherbourneC. The MOS 36-item short-form health survey (SF-36). Med Care 1992;30:473–81.

References

1. World Health Organization. International Classification of Functioning Disability and Health. Geneva: WHO, 2004.
2. JainS, KingsJ, PlayfordED. Occupational therapy for people with progressive neurological disorders: unpacking the black box. Br J Occ Ther 2005;68;125–30.
3. MeekC, MorganE, WalkerMF, et al. Occupational therapy to optimise independence in Parkinson’s disease: the designing and recording of a randomised controlled trial intervention. Br J Occ Ther 2010;73;178–85.
4. SilvaRC, SauteJA, SilvaAC, et al. Occupational therapy in spinocerebellar ataxia type 3: an open-label trial. Braz J Med Biol Res 2010;43;537–42.
5. JainS, DawsonJ, QuinnNP, PlayfordED. Occupational therapy in multiple system atrophy: a pilot randomised controlled trial. Mov Disord 2004;19;1360–4.
6. DixonL, DuncanDC, JohnsonP, et al. Occupational therapy for patients with Parkinson’s disease. Cochrane Database System Rev 2007:3:CD002813.
7. AragonA, Kings, J. Occupational Therapy for People with Parkinson’s: Best Practice Guidelines. London: College of Occupational Therapists, 2010.
8. Progressive Supranuclear Palsy Association. A Guide to PSP and CBD for Occupational Therapists. Towcester: PSP Association, 2008.
9. AtaxiaUK. Management of the Ataxias: Towards Best Clinical Practice. London: Ataxia UK, 2009.
10. MyersC. The Many Faces of Huntington’s Disease Part II: Occupational therapy’s role in improving quality of life. Advance,2007;23:32. See: http://occupational-therapy.advanceweb.com/Article/The-Many-Faces-of-Huntingtons-Disease-1.aspx [accessed 29.4.2012].
11. ReismanDS, BastianAJ, MortonSM. Neurophysiologic and rehabilitation insights from the split-belt and other locomotor adaptation paradigms. Phys Ther 2010;90;187–95.
12. FarleyB, KoshlandG. Training BIG to move faster: the application of the speed amplitude relation as a rehabilitation strategy for people with Parkinson’s disease. Exp Brain Res 2005;167;462–7.
13. BehrmanAL, CauraughJH, LightKE. Practice as an intervention to improve speeded motor performance and motor learning in Parkinson’s disease. J Neurol Sci 2000;174;127–36.
14. MarcheseR, DiverioM, ZucchiF, et al. The role of sensory cues in the rehabilitation of parkinsonian patients: a comparison of two physical therapy protocols. Mov Disord 2000;15;879–83.
15. FokP, FarrellM, McMeekenJ, KuoYL. The effects of verbal instructions on gait in people with Parkinson’s disease: a systematic review of randomized and non-randomized trials. Clin Rehabil 2011;25;396–407.
16. KuoAD, DonelanJM. Dynamic principles of gait and their clinical implications. Phys Ther 2010;90;157–74.
17. MorrisME, MartinCL, SchenkmanML. Striding out with Parkinson disease: evidence-based physical therapy for gait disorders. Phys Ther 2010;90:280–8.
18. MorrisME, IansekR, GalnaB. Gait festination and freezing in Parkinson’s disease: pathogenesis and rehabilitation. Mov Disord 2008;23:S451–60.
19. CanningCG, AdaL, WoodhouseE. Multiple-task walking training in people with mild to moderate Parkinson’s disease: a pilot study. Clin Rehabil 2008;22;226–33.
20. NieuwboerA, KwakkelG, RochesterL, et al. Cueing training in the home improves gait-related mobility in Parkinson’s disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007;78;134–7.
21. LehmanDA, TooleT, LofaldD, HirschMA. Training with verbal instructional cues results in near-term improvement of gait in people with Parkinson disease. J Neurol Phys Ther 2005;29;2–8.
22. ProtasEJ, MitchellK, WilliamsA, et al. Gait and step training to reduce falls in Parkinson’s disease. NeuroRehab 2005;20;183–90.
23. RochesterL, HetheringtonV, JonesD, et al. The effect of external rhythmic cues (auditory and visual) on walking during a functional task in homes of people with Parkinson’s disease. Arch Phys Med Rehabil 2005;86:999–1006.
24. JansaJ, AragonA, Lundgren-NillsonA. How people living with Parkinson’s disease in four European countries view occupational therapy. Eur Neurol J 2011;3;1.
25. Parkinson’s Disease Society. Life with Parkinson’s Today – Room for Improvement. London: Parkinson’s Disease Society, 2008.
26. EstherMJ, SteultjensEMJ, DekkerJ, et al. Evidence of the efficacy of occupational therapy in different conditions: an overview of systematic reviews. Clin Rehabil 2005;19;247–54.
27. AldrichJ. Correlations genuine and spurious. Statistical Sci 1995;10;364–76.
28. NijkrakeMJ, KeusSH, OvereemS, et al. The ParkinsonNet concept: development, implementation and initial experience. Mov Disord 2010;25;823–9.
29. LawM, BaptisteS, CarswellA, et al. Canadian Occupational Performance Measure, 4th edition. Ottawa, Ontario: Canadian Association of Occupational Therapists, 2005.
30. FisherAG. Assessment of Motor and Process Skills, 5th edition. Fort Collins: Three Star Press, 2003.
31. KeilhofnerGA. Model of Human Occupation: Theory and Application. 3rd edition. Philadelphia: Lippincott Williams and Wilkins, 2002.
32. DeaneKHO, Ellis-HillC, DaviesP, ClarkeCE. A survey of current occupational therapy practise for Parkinson’s disease in the United Kingdom. Br J Occ Ther 2003;66;193–200.
33. DeaneKHO, Ellis-HillC, DaviesP, ClarkeCE. A Delphi survey of best practise occupational therapy for Parkinson’s disease in the United Kingdom. Br J Occ Ther 2003;66;247–54.
34. HollidayRC, AtounM, PlayfordED. A survey of goal-setting methods used in rehabilitation. Neurorehab Neural Repair 2005;19;227–31.
35. PlayfordED, DawsonL, LimbertV, et al. Goal-setting in rehabilitation: report of a workshop to explore professionals’ perceptions of goal-setting. Clin Rehabil 2000;14;491–6.
36. DonnellyC, EngJJ, HallJ, et al. Client-centred assessment and the identification of meaningful treatment goals for individuals with a spinal cord injury. Spinal Cord 2004;42;302–7
37. van den BroekMD. Why does neurorehabilitation fail?J Head Trauma Rehabil 2005;20;464–73.
38. WressleE, Eeg-OlofssonA-M, MarcussonJ, HenrikssonC. Improved client participation in the rehabilitation process using a client-centred goal formulation structure. J Rehabil Med 2002;34;5–11.
39. HerschGI, LampertNK, CoffeyMS. Activity Analysis: Applications to Occupation, 5th edition. Thorofare, NJ: SLACK Inc., 2005.
40. FergusonJM, TromblyCA. The effect of added purpose and meaningful occupation on motor relearning. Am J of Occ Ther 1998;51;508–15.
41. MaH, TromblyCA. The effect of context on skills acquisition and transfer. Am J Occ Ther 1999;53;138–44.
42. Department of Health Chief Health Professions Officer. What are allied health professionals? See: http://www.dh.gov.uk/en/Aboutus/Chiefprofessionalofficers/Chiefhealthprofessionsofficer/DH_4136332 [accessed 29.4.2012].
43. SweetlandJ, RiaziA, CanoSJ, PlayfordED. Vocational rehabilitation services for people with multiple sclerosis: what patients want from clinicians and employers. Multiple Sclerosis 2007;13;1183–9.
44. HeinemannAW, CorriganJD, MooreD. Case management for traumatic brain injury survivors with alcohol problems. Rehabil Psychol 2004;49;156–66.
45. GruberRA, ElmanJG, HuijbregtsMPJ. Self-management programs for people with Parkinson’s disease – a program evaluation approach. Geriatric Rehabil 2008;24;141–50.

References

1. Association of Rehabilitation Nurses. Standards and Scope of Rehabilitation Nursing Practice, 5th edition. Schaumburg, IL: Glenview, 2008.
2. Australasian Rehabilitation Nurses’ Association. Rehabilitation nursing – scope of practice. JARNA 1999;2:14–15.
3. SkirtonH, WilliamsJK, Jackson BarnetteJ, PaulsenJS. Huntington disease: families’ experiences of healthcare services. J Adv Nursing 2010;66:500–10.
4. TanSB, WilliamsAF, MorrisME. Experiences of caregivers of people with Parkinson’s disease in Singapore: a qualitative analysis. J Clin Nursing 2012;21:2235–46.
5. WHOQOL. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 1995;41:1405.
6. GordonM. Nursing Diagnosis: Process and Application, 3rd edition: Mosby, MO: St. Louis, 1994.
7. PryorJ, SmithC. A framework for the role of Registered Nurses in the specialty practice of rehabilitation nursing in Australia. J Adv Nursing 2002;39:249–57.
8. GoetzCG. Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS–UPDRS): a new scale for the evaluation of Parkinson’s disease. Rev Neurol 2010;166:1–4.
9. DoddsTA, MartinDP, StolovWC, DeyoRA. A validation of the functional independence measurement and its performance among rehabilitation inpatients. Arch Phys Med Rehabil 1993;74:531.
10. TimmanR, ClausH, SlingerlandH, et al. Nature and development of Huntington disease in a nursing home population: the Behavior Observation Scale Huntington (BOSH). Cognit Behav Neurol 2005;18:215.
11. TombaughTN, McDowellI, KristjanssonB, HubleyAM. Mini Mental State Examination (MMSE) and the Modified MMSE (3MS): a psychometric comparison and normative data. Psychol Assessment 1996;8:48.
12. RemsbergR, CarsonB. Rehabilitation. In LubkinIM, LarsenPD, eds. Chronic Illness: Impact and Interventions, 5th edition. Sudbury, MA: Jones & Bartlett, 2006;579–616.
13. SenardJM, Brefel-CourbonC, RascolO, MontastrucJL. Orthostatic hypotension in patients with Parkinson’s disease: pathophysiology and management. Drugs Aging 2001;18:495–505.
14. SenardJM, RaiS, Lapeyre-MestreM, et al. Prevalence of orthostatic hypotension in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997;63:584–9.
15. MakMKY, PangMYC. Fear of falling is independently associated with recurrent falls in patients with Parkinson’s disease: a 1-year prospective study. J Neurol 2009;256:1689–95.
16. Tickle-DegnenL, LyonsKD. Practitioners’ impressions of patients with Parkinson’s disease: the social ecology of the expressive mask. Soc Sci Med 2004;58:603–14.
17. JankovicJ. Parkinson’s disease therapy: tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol 2000;23:252–61.
18. Martinez-MartinP, ArroyoS, ManuelJ, et al. Burden, perceived health status, and mood among caregivers of Parkinson’s disease patients. Mov Disord 2008;23:1673–80.
19. HaynesRB, AcklooE, SahotaN, McDonaldHP, YaoX. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008;2:CD000011.
20. JadadAR, BrowmanGP. The WHO analgesic ladder for cancer pain management. JAMA 1995;274:1870.
21. DeweyRBJ. Autonomic dysfunction and management. In PahwaR, LyonsKE, eds. Handbook of Parkinson’s Disease, 4th edition. New York: Dekker, 2007; 77–91.
22. DubowJS. Autonomic dysfunction in Parkinson’s disease. Dis Mon 2007;53:265.
23. VeenhuizenRB, TibbenA. Coordinated multidisciplinary care for Huntington’s disease. an outpatient department. Brain Res Bull 2009;80:192–5.
24. CannasA, SollaP, FlorisGL, et al. Aberrant sexual behaviours in Parkinson’s disease during dopaminergic treatment. J Neurol 2007;254:110–12.
25. StameyW, JankovicJ. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist 2008;14:89–99.
26. DoddML, KlosKJ, BowerJH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62:1377–81.
27. GlosserG, ClarkC, FreundlichB, et al. A controlled investigation of current and premorbid personality: characteristics of Parkinson’s disease patients. Mov Disord 1995;10:201–6.
28. AarslandD, LarsenJP, LimNG, et al. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999;67(4):492–6.
29. KarlsenKH, TandbergE, ArslandD, LarsenJP. Health related quality of life in Parkinson’s disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 2000;69:584–9.
30. SchenkmanM, CutsonTM, ZhuCW, Whetten-GoldsteinK. A longitudinal evaluation of patients; perceptions of Parkinson’s disease. Gerontologist 2002;42:790–8.
31. LeiknesI, Tysnes, Aarsland D, LarsenJP. Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson’s disease: The Norwegian ParkWest study. Acta Neurologica Scand 2010;122:418–24.
32. SchragA, BaroneP, BrownRG, et al. Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 2007; 22: 1077–92
33. MearaJ, MichelmoreE, HobsonP. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson’s disease and their carers in the community. Age Ageing 1999;28:35–8.
34. LemackG, DeweyR, RoehrbornC, O’SuilleabhainP, ZimmernP. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson’s disease. Urology. 2000;56:250–4.
35. MooreK, FaderM, GetliffeK. Long-term bladder management by intermittent catheterisation in adults and children. Cochrane Database SystemRev 2007;4:CD006008.
36. JahnP, PreussM, KernigA, LangerG, Seifert-HuehmerA, eds. Types of indwelling urinary catheters for long-term bladder drainage in adults. Cochrane Database System Rev 2007:3:CD004997.
37. ArakiI, KitaharaM, OidaT, KunoS. Voiding dysfunction and Parkinson’s disease: urodynamic abnormalities and urinary symptoms. J Urol 2000;164:1640–3.
38. JepsonR, CraigJC, eds. Cranberries for preventing urinary tract infections. Cochrane Database System Rev 2008;1:CD001321.
39. AvornJ, MonaneM, GurwitzJH, et al. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA 1994;271(10):751–4.
40. PfeifferR. Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 2011;17:10.
41. EdwardsLL, PfeifferRF, QuigleyEMM, HofmanR, BalluffM. Gastrointestinal symptoms in Parkinson’s disease. Mov Disord 1991;6:151–6.
42. Dilworth-AndersonP, WilliamsIC, GibsonBE. Issues of race, ethnicity, and culture in caregiving research: a 20-year review (1980–2000). Gerontologist 2002;42:237–72.
43. CarterJH, StewartBJ, LyonsKS, ArchboldPG. Do motor and nonmotor symptoms in PD patients predict caregiver strain and depression?Mov Disord 2008;23:1211–16.
44. AyresL. Narratives of family caregiving: the process of making meaning. Res Nursing Health 2000;23:424–34.
45. WilliamsJK, BarnetteJJ, ReedD, et al. Development of the Huntington Disease Family Concerns and Strategies Survey from focus group data. J Nursing Measurement 2010;18:83–99.
46. McLennonSM, HabermannB, DavisLL. Deciding to institutionalize: why do family members cease caregiving at home?J Neurosci Nursing 2010;42:95–103.
47. DorseyER, VossTS, ShprecherDR, et al. A U.S. survey of patients with Parkinson’s disease: satisfaction with medical care and support groups. Mov Disord 2010;25:2128–35.
48. EllisT, KatzD, WhiteD, et al. Effectiveness of a specialized, multidisciplinary, inpatient movement disorders rehabilitation program for patients with Parkinson’s disease. Neurorehabil Neural Repair 2005;19:363.
49. SitziaJ, HaddrellV, Rice-OxleyM. Evaluation of a nurse-led multidisciplinary neurological rehabilitation programme using the Nottingham Health Profile. Clin Rehabil 1998;12:389–94.
50. A’CampoLEI, WekkingEM, Spliethoff-KammingaNGA, Le CessieS, RoosRAC. The benefits of a standardized patient education program for patients with Parkinson’s disease and their caregivers. Parkinsonism Relat Disord 2010;16:89–95.
51. BeachS. Religiosity as a predictor of positive reactions to caregiving: findings from the caregiver health effects study. Gerontologist 2005;45:629.
52. TanSB, WilliamsAF, MorrisM, TanEK. Health-related quality of life of caregivers of people with Parkinson’s disease in Singapore. Proc Singapore Healthcare 2010;19(4).
53. RolandKP, JenkinsME, JohnsonAM. An exploration of the burden experienced by spousal caregivers of individuals with Parkinson’s disease. Mov Disord 2010;25:189–93.

References

1. SchragA, JahanshahiM, QuinnNP. What contributes to quality of life in patients with Parkinson’s disease?J Neurol Neurosurgery & Psychiatry 2000;69:308–312.
2. LezakM. Neuropsychological Assessment, 4th Edition. New York: Oxford University Press, 2004.
3. JahanshahiM, JenkinsIH, BrownRG, et al. Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson’s disease subjects. Brain 1995;118:913–33.
4. JahanshahiM, ArdouinC, BrownRG, et al. The impact of deep brain stimulation on executive function in Parkinson’s disease. Brain 2000;123:1142–54.
5. DirnbergerG, FrithCD, JahanshahiM. Executive dysfunction in Parkinson’s disease is associated with altered pallidal-frontal processing. Neuroimage 2005;25:588–99.
6. Floyer-LeaA, MatthewsPM. Distinguishable brain activation networks for short- and long-term motor skill learning. J Neurophysiol 2005;94:512–18.
7. JahanshahiM, RothwellJC. Transcranial magnetic stimulation studies of cognition: An emerging field. Exp Brain Res 2000;131:1–9.
8. RepovsG, BaddeleyA. The multi-component model of working memory: explorations in experimental cognitive psychology. Neuroscience 2006;139:5–21.
9. NormanDA, ShalliceT. Attention to action: willed and automatic control of behaviour. In RJ Davidson, GE Schwartz & DA Shapiro, eds. Consciousness and Self-regulation, Volume 4, New York: Plenum, 1986; 1–18.
10. MillerEK, CohenJD. An integrative theory of prefrontal cortex function. Annu Rev Neurosci 2001;24:167–202.
11. AlexanderGE, DeLongMR, StrickPL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357–81.
12. MiddletonFA, StrickPL. The temporal lobe is a target of output from the basal ganglia. Proc Natl Acad Sci USA 1996;93:8683–7.
13. ClowerDM, DumRP, StrickPL. Basal ganglia and cerebellar inputs to ‘AIP’. Cerebr Cortex 2005;15:913–20.
14. DraganskiB, KherifF, KloeppelS, et al. Evidence for segregated and integrative connectivity patterns in the human basal ganglia. J Neurosci 2008;28:7143–52.
15. LehericyS, DucrosM, Van de MoortelePF, et al. Diffusion tensor fiber tracking shows distinct corticostriatal circuits in humans. Ann Neurol 2004;55:522–9.
16. CummingsJL. Frontal-subcortical circuits and human behavior. Arch Neurol 1993;50:873–80.
17. JahanshahiM, FrithCD. Willed action and its impairments. Cogn Neuropsychol 1998;15:483–533.
18. ArdouinC, PillonB, PeifferE, et al. Bilateral subthalamic or pallidal stimulation for Parkinson’s disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol 1999;46:217–23.
19. JahanshahiM, RoweJ, SaleemT, et al. Striatal contribution to cognition: working memory and executive function in Parkinson’s disease before and after unilateral pallidotomy. J Cognit Neurosci 2002;14:298–310.
20. PillonB, ArdouinC, DujardinK, et al. Preservation of cognitive function in dystonia treated by pallidal stimulation. Neurology 2006;66:1556–8.
21. HalbigTD, GruberD, KoppUA, et al. Pallidal stimulation in dystonia: effects on cognition, mood, and quality of life. J Neurol Neurosurg Psychiatry 2005;76:1713–16.
22. JahanshahiM, CzerneckiV, ZurowskiAM. Neuropsychological, neuropsychiatric, and quality of life issues in DBS for dystonia. Mov Disord 2011;26:S63–78.
23. EmreM, AarslandD, BrownR, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007;22:1689–707.
24. DuboisB, BurnD, GoetzC, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the Movement Disorder Society Task Force. Mov Disord 2007;22:2314–24.
25. MattisS. Dementia Rating Scale Professional Manual. Odessa, FL: Psychological Assessment Resources, Inc, 1988.
26. CummingsJL, MegaM, GrayK, Rosenberg-ThompsonS, CarusiDA, GornbeinJ. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–14.
27. FolsteinMF, FolsteinSE, McHughPR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psych Res 1975;12:189–98.
28. NasreddineZS, PhillipsNA, BedirianV, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatric Soc 2005;53:695–9.
29. DuboisB, SlachevskyA, LitvanI, PillonB. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000;55:1621–6.
30. PaviourDC, WinterburnD, SimmondsS, et al. Can the frontal assessment battery (FAB) differentiate bradykinetic rigid syndromes? Relation of the FAB to formal neuropsychological testing. Neurocase 2005;11:274–82.
31. RobbinsTW, JamesM, OwenAM, et al. Cognitive deficits in progressive supranuclear palsy, Parkinson’s disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry 1994;57:79–88.
32. PagonabarragaJ, KulisevskyJ, LlebariaG, et al. Parkinson’s Disease – Cognitive Rating Scale: a new cognitive scale specific for Parkinson’s disease. Mov Disord 2008;23:998–1005.
33. KalbeE, CalabreseP, NilsK, et al. Screening for cognitive deficits in Parkinson’s disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism Relat Disord 2008;14:93–101.
34. MarinusJ, VisserM, VerweyNA, et al. Assessment of cognition in Parkinson’s disease. Neurology 2003;61:1222–8.
35. KulisevskyJ, PagonabarragaJ. Cognitive impairment in Parkinson’s disease: tools for diagnosis and assessment. Mov Disord 2009;24:1103–10.
36. SchragA, BaroneP, BrownRG, et al. Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 2007;22:1077–92.
37. LeentjensA, DujardinK, MarshL, et al. Anxiety rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 2008;23:2015–25.
38. LeentjensA, DujardinK, MarshL, et al. Apathy and anhedonia rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 2008;23:2004–14.
39. FriedmanJH, AlvesG, HagellP, MarinusJ, MarshL, Martinez-MartinP, GoetzCG, PoeweW, RascolO, SampaioC, StebbinsG, SchragA. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson’s disease. Mov Disord 2010 May 15;25(7):805–22. doi: 10.1002/mds.22989. Review
40. FernandezHH, AarslandD, FenelonG, et al. Scales to assess psychosis in Parkinson’s disease: critique and recommendations. Mov Disord 2008;23:484–500.
41. GothamAM, BrownRG, MarsdenCD: ‘Frontal’ cognitive function in patients with Parkinson’s disease ‘on’ and ‘off’ levodopa. Brain 1988;111:299–321.
42. CoolsR. Dopaminergic modulation of cognitive function – implications for L-DOPA treatment in Parkinson’s disease. Neurosci Biobehav Rev 2006;30:1–23.
43. JahanshahiM, WilkinsonL, GahirH, DharmindaA, LagnadoDA. Medication impairs probabilistic classification learning in Parkinson’s disease. Neuropsychologia 2010;48:1096–103.
44. TaylorAE, Saint-CyrJA, LangA. Frontal lobe dysfunction in Parkinson’s disease: the cortical focus of neostriatal outflow. Brain 1986;109:279–92.
45. OwenAM, IddonJL, HodgesJR, SummersBA, RobbinsTW. Spatial and non-spatial working memory at different stages of Parkinson’s disease. Neuropsychologia 1997;35:519–32.
46. BrownRG, SoliveriP, JahanshahiM. Executive processes in Parkinson’s disease – random number generation and response suppression. Neuropsychologia 1998;36:1355–62.
47. ObesoI, WilkinsonL, CasabonaE, BringasML, ÁlvarezM, ÁlvarezL, PavónN, Rodríguez-OrozMC, MacíasR, ObesoJA, JahanshahiM. Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson’s disease. Exp Brain Res 2011 Jul;212(3):371–84.
48. BrownRG, MarsdenCD. Internal versus external cues and the control of attention in Parkinson’s disease. Brain 1988;111:323–45.
49. BoeveB. Parkinson-related dementias. Neurol Clin 2007;25:761–81.
50. WhittingtonCJ, PoddJ, KanMM. Recognition memory impairment in Parkinson’s disease: power and meta-analysis. Neuropsychology 2000;14:233–46.
51. ElghE, DomellofM, LinderJ, et al. Cognitive function in early Parkinson’s disease: a population-based study. Eur J Neurol 2009;16:1278–84.
52. AarslandD, BrønnickK, AlvesG, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatr 2009;80;928–30.
53. LevyG, TangMX, CoteLJ, et al. Do risk factors for Alzheimer’s disease predict dementia in Parkinson’s disease?Mov Disord 2002;17:250–7.
54. Williams-GrayCH, FoltynieT, BrayneCE, RobbinsTW, BarkerRA. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 2007;130:1787–98.
55. WeintraubD, KoesterJ, PotenzaMN, et al. Impulse control disorders in Parkinson disease a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589–95.
56. SchragA, SheikhS, QuinnNP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 2010;25:1077–81.
57. AlbertM, FeldmanRG, WillisAL. The ‘subcortical dementia’ of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1974;37:121–30.
58. LeiguardaRC, PramstallerPP, MerelloM, et al. Apraxia in Parkinson’s disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. Brain 1997;120:75–90.
59. PirtosekZ, JahanshahiM, BarrettG, LeesAJ. Attention and cognition in bradykinetic-rigid syndromes: an event-related potential study. Ann Neurol 2001;50:567–73.
60. LitvanI, MangoneCA, McKeeA, et al. Natural history of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996;60:615–20.
61. DuboisB, PillonB, LegaultF, AgidY, LhermitteF. Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson’s disease. Arch Neurol 1988;45:1194–9.
62. PillonB, BlinJ, VidailhetM, et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer’s disease. Neurology 1995;45:1477–83.
63. SoliveriP, MonzaD, ParidiD, et al. Neuropsychological follow up in patients with Parkinson’s disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2000;69:313–18.
64. DujardinK, DefebvreL, KrystkowiakP, et al. Executive function differences in multiple system atophy and Parkinson’s disease. Parkinsonism Relat Disord 2003;9:205–11.
65. BrownRG, LacomblezL, LandwehrmeyerBG, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010;133:2382–93.
66. LitvanI, CummingsJ, MegaM. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998;65:717–21.
67. KawaiY, SuenagaM, TakedaA, et al. Cognitive impairments in multiple system atrophy: MSA-C vs MSA-P. Neurology 2008;70:1390–6.
68. ColosimoC, MorganteL, AntoniniA, et al. Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol 2010;257:5–14.
69. GrahamN, BakT, HodgesJ. Corticobasal degeneration as a cognitive disorder. Mov Disord 2003;18:1224–32.
70. GedaYE, BoeveBF, NegashS, et al. Neuropsychiatric features in 36 pathologically confirmed cases of corticobasal degeneration. J Neuropsychiatry Clin Neurosci 2007;19:77–80.
71. BrandtJ, ButtersN. The neuropsychology of Huntington’s disease. Rends Neurosci 1986;9:118–20.
72. HoA, SahakianB, BrownR, et al. Profile of cognitive progression in early Huntington’s disease. Neurology 2003;61:1702–6.
73. DuffK, PaulsenJ, MillsJ, et al. Mild cognitive impairment in prediagnosed Huntington disease. Neurology 2010;75:500–7.
74. PaulsenJS, NehlC, HothKF, et al. Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci 2005;17:496–502.
75. JahanshahiM, RoweJ, FullerR. Impairment of movement initiation and execution but not preparation in idiopathic dystonia. Exp Brain Res 2001;140:460–8.
76. LombardiWJ, WoolstonDJ, RobertsJW, GrossRE. Cognitive deficits in patients with essential tremor. Neurology 2001;57:785–90.
77. BakT, CrawfordL, HearnV, MathuranathP, HodgesJ. Subcortical dementia revisited: similarities and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). Neurocase 2005;11:268–73.
78. MayeuxR, SternY. Intellectual dysfunction and dementia in Parkinson disease. Adv Neurol 1983;38:211–27.
79. BrownRG, MarsdenCD. Subcortical dementia: the neuropsychological evidence. Neuroscience 1988;25:363–87.
80. JahanshahiM, BrownRG, MarsdenCD. Simple and choice reaction time and the use of advance information for motor preparation in Parkinson’s disease. Brain 1992;115:539–64.
81. JahanshahiM, BrownRG, MarsdenCD. A comparative study of simple and choice reaction time in Parkinson’s, Huntington’s and cerebellar disease. J Neurol Neurosurg Psychiatry 1993;56:1169–77.
82. JahanshahiM, HallettM, eds. The Bereitschaftspotential. Movement-Related Cortical Potentials. Dordrecht: Kluwer-Plenum, 2003.
83. PastorMA, ArtiedaJ, JahanshahiM, ObesoJA. Time estimation and reproduction is abnormal in Parkinson’s disease. Brain 1992;115:211–25.
84. JonesC, MaloneT, DirnbergerG, EdwardsM, JahanshahiM. Basal ganglia, dopamine and temporal processing: performance on three timing tasks on and off medication in Parkinson’s disease. Brain Cognit, 2008;68:30–41.
85. JahanshahiM, JonesCRG, ZijlmansJ, et al. Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson’s disease. Brain 2010;133:727–45.
86. BradleyD, WhelanR, WalshR, et al. Temporal discrimination threshold: VBM evidence for an endophenotype in adult onset primary torsion dystonia. Brain 2009;132:2327–35.
87. BesteC, SaftC, AndrichJ, et al. Time processing in Huntington’s disease: a group-control study. PLOS ONE 2007;2:e1263.
88. RedgraveP, RodriguezM, SmithY, et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson’s disease. Nat Rev Neurosci 2010;11:760–72.
89. BrownRG, MarsdenCD. Dual task performance and processing resources in normal subjects and patients with Parkinson’s disease. Brain 1991 Feb;114(Pt 1A):215–31.
90. BeneckeR, RothwellJC, DickJP, DayBL, MarsdenCD. Performance of simultaneous movements in patients with Parkinson’s disease. Brain 1986;109:739–57.
91. BrownRG, JahanshahiM, MarsdenCD. The execution of bimanual movements in patients with Parkinson’s, Huntington’s and cerebellar disease. J Neurol Neurosurg Psychiatry 1993;56:295–7.
92. AronAR, SchlagheckenF, FletcherPC, BullmoreET, EimerM, BarkerR, SahakianBJ, RobbinsTW. Inhibition of subliminally primed responses is mediated by the caudate and thalamus: evidence from functional MRI and Huntington’s disease. Brain 2003;126:713–23.
93. DirnbergerG, NovakJ, NaselC, ZehnterM. Separating coordinative and executive dysfunction in cerebellar patients during motor skill acquisition. Neuropsychologia 2010;48:1200–8.
94. ZinziP, SalmasoD, De GrandisR, et al. Effects of an intensive rehabilitation programme on patients with Huntington’s disease: a pilot study. Clin Rehabil 2007;21:603–13.
95. NieuwboerA, RochesterL, MuncksL, SwinnenSP. Motor learning in Parkinson’s disease: limitations and potential for rehabilitation. Parkinsonism Relat Disord 2009;15:53–8.
96. WilkinsonL, JahanshahiM. The striatum and probabilistic implicit sequence learning. Brain Res 2007;1137:117–30.
97. WilkinsonL, KhanZ, JahanshahiM. The role of the basal ganglia and its cortical connections in sequence learning: evidence from implicit and explicit sequence learning in Parkinson’s disease. Neuropsychologia 2009;47:2564–73.
98. SchneiderSA, WilkinsonL, BhatiaKP, et al. Abnormal explicit but normal implicit sequence learning in premanifest and early Huntington’s disease. Mov Disord 2010;25:1343–9.
99. MorrisME. Movement disorders in people with Parkinson disease: a model for physical therapy. Phys Ther 2000;80:578–97.
100. GriffinH, GreenlawR, LimousinP, et al. The effect of real and virtual visual cues on walking in Parkinson’s disease. J Neurol 2011;258:991–1000.
101. LimI, van WegenE, de GoodeC, et al. Effects of external rhythmical cueing on gait in patients with Parkinson’s disease: a systematic review. Clin Rehabil 2005;19:695–713.
102. OliveiraRM, GurdJM, NixonP, et al. Micrographia in Parkinson’s disease: the effect of providing external cues. J Neurol Neurosurg Psychiatry. 1997;63:429–33.
103. BassettS. Cognitive impairment in Parkinson’s disease. Primary Psychiatry 2005;12:50–5.
104. SpeelmanAD, van de WarrenburgBP, van NimwegenM, et al. Physical activity benefit patients with Parkinson disease?Nat Rev Neurol 2011;7:528–34.
105. SubramanianL, HindleJV, JohnstonS, et al. Real-time functional magnetic resonance imaging neurofeedback for treatment of Parkinson’s disease. J Neurosci 2011;31:16309–17.
106. SinforianiE, BanchieriL, ZucchellaC, PacchettiC, SandriniG. Cognitive rehabilitation in Parkinson’s disease. Arch Gerontol Geriatr 2004;9:S387–91.
107. RidgelAL, KimCH, FickesEJ, MullerMD, AlbertsJL. Changes in executive function after acute bouts of passive cycling in Parkinson’s disease. J Aging Phys Act 2011;19:87–98.
108. TaubE, UswatteG, ElbertT. New treatments in neurorehabilitation founded on basic research. Nat Rev Neurosci 2002;3:228–36.
109. Pascual-LeoneA. Akinesia in Parkinson’s disease. I. Shortening of simple reaction time with focal, single-pulse TMS. Neurology 1994;44:884–91.
110. SiebnerHR, RossmeierC, MentschelC, PeinemannA, ConradB. Short-term motor improvement after sub-threshold 5-Hz repetitive transcranial magnetic stimulation of the primary motor hand area in Parkinson’s disease. J Neurol Sci 2000;178: 91–4.
111. DobkinRD, MenzaM, AllenLA, et al. Telephone-based cognitive-behavioral therapy for depression in Parkinson disease. J Geriatr Psychiatry Neurol 2011;24:206–14.
112. SeckerDL, BrownRG. Cognitive behavioural therapy (CBT) for carers of patients with Parkinson’s disease: a preliminary randomised controlled trial. J Neurol Neurosurg Psychiatry 2005;76:491–7.

References

1. DuffyJR. Motor Speech Disorders. Substrates, Differential Diagnosis, And Management, 2nd edition. St. Louis: Elsevier Mosby, 2005.
2. DuffyJF. Hypokinetic dysarthria. In DuffyJR, ed. Motor Speech Disorders. Substrates, Differential Diagnosis, And Management. 2nd edition. St. Louis: Elsevier Mosby, 2005;187–215.
3. HarteliusL, SvenssonP. Speech and swallowing symptoms associated with Parkinson’s disease and multiple sclerosis – a survey. Folia Phoniatr Logo 1994;46:9–17.
4. LogemanJA, FisherHB, BoshesB, BlonskyER. Frequency and co occurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson patients. J Speech Hear Disord 1978;43:47–57.
5. MillerN, NobleE, JonesD, AllcockL, BurnDJ. How do I sound to me? Perceived changes in communication in Parkinson’s disease. Clin Rehab 2008;22:14–22.
6. MillerN, NobleE, JonesD, BurnD. Life with communication changes in Parkinson’s disease. Age Ageing 2006;35:235–9.
7. MillerN, AllcockL, JonesD, et al. Prevalence and pattern of perceived intelligibility changes in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78:1188–90.
8. FoxC, Morrison, CE, RamigLO, SapirS. Current perspectives on the Lee Silverman Voice Treatment (LSVT) for people with idiopathic Parkinson’s disease. Am J Speech Lang Path 2002;11:111–23.
9. AdamsSG, HaralabousO, DykstraA, AbramsK, JogMS. Effects of multi-talker background noise on the intensity of spoken sentences in Parkinson’s disease. Can Acoust 2005;33:94–5.
10. FoxC, RamigLO. Vocal sound pressure level and self-perception of speech and voice in men and women with idiopathic Parkinson disease. Am J Speech Lang Path 1997;39:85–94.
11. Plowman-PrineEK, OkunMS, SapienzaCM, et al. Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems. NeuroRehab 2009;24:131–44.
12. LogemannJA, FisherHB. Vocal tract control in Parkinson’s disease: phonetic feature analysis of misarticulations. J Speech Hear Disord 1981;46:348–52.
13. ForrestK, WeismerG, TurnerGS. Kinematic, acoustic, and perceptual analyses of connected speech produced by parkinsonian and normal geriatric patients. J Acoust Soc Am 1989;85:2608.
14. SapirS, RamigL, FoxC. Assessment and treatment of the speech disorder in Parkinson disease. In TheodorosD, RamigL, eds. Communication and Swallowing in Parkinson Disease. San Diego: Plural Publishing, 2011;89–122.
15. HoAK, IansekR, BradshawJL. Motor instability in parkinsonian speech intensity. Neuropsy Neuropsy Behav Neurol. 2001;14:109–16.
16. SapirS, RamigLO, SpielmanJL, FoxC. Formant Centralization Ratio (FCR): a proposal for a new acoustic measure of dysarthric speech. J Speech Lang Hear Res 2012;53:114–25.
17. SkoddaS, VisserW, SchlegelU. Vowel articulation in Parkinson’s disease. J Voice 2011;25:467–72.
18. DiamondSG, SchneiderJS, MarkhamCH. Oral sensorimotor defects in people with Parkinson’s disease. Adv Neurol 1987;45:335–8.
19. HammerMJ, BarlowSM. Laryngeal somatosensory deficits in Parkinson’s disease: implications for speech respiratory and phonatory control. Exp Brain Res 2010;201:401–9.
20. DemirciM, GrillS, McShaneL, HalletM. Impairment of kinesthesia in Parkinson’s disease. Neurology 1995;45:A218.
21. HalletM. Sensorimotor integration and mysterious sensory phenomena in movement disorders. In HalletM, ed. Motor Control. Minneapolis: American Academy of Neurology, 1997.
22. GraberS, HertrichI, DaumI, SpiekerS, AckermannH. Speech perception deficits in Parkinson’s disease: underestimation of time intervals compromises identification of durational phonetic contrasts. Brain Lang 2002;82:65–74.
23. HoAK, BradshawJL, IansekR. Volume perception in parkinsonian speech. Mov Disord 2000;15:1125–31.
24. HoAK, IansekR, BradshawJL. Regulation of parkinsonian speech volume: the effect of interlocutor distance. J Neurol Neurosurg Psychiatry. 1999;67:199–202.
25. HoAK, BradshawJL, IansekR, AlfredsonR. Speech volume regulation in Parkinson’s disease: effects of implicit cues and explicit instructions. Neuropsychologia 1999;37:1453–60.
26. DromeyC, RamigL. Intentional changes in sound pressure level and rate: their impact on measures of respiration, phonation, and articulation. J Speech Lang Hear Res 1998;41:1003–18.
27. DuffyJF. Hyperkinetic dysarthria. In DuffyJR, ed. Motor Speech Disorders. Substrates, Differential Diagnosis, And Management. 2nd edition. St. Louis: Elsevier Mosby, 2005;217–53.
28. ZraickRI, LaPointeLL. Hyperkinetic dysarthria. In McNeilMR, ed. Clinical Management of Sensorimotor Speech Disorders, 2nd edition. New York: Thieme, 2009;152–65.
29. World Health Organization. International Classification of Functioning, Disability and Health. Geneva: WHO, 2001.
30. EnderbyP. Huntington’s Disease. In McNeilMR, ed. Clinical Management of Sensorimotor Speech Disorders, 2nd edition. New York: Thieme, 2009;331–3.
31. JankovicJTardive syndromes and other drug-induced movement disorders. Clin Neuropharm 1995;18:197–214.
32. YorkstonKM, HakelM, BeukelmanDR, FaerS. Evidence for effectiveness of treatment of loudness, rate, or prosody in dysarthria: a systematic review. J Med Speech Lang Pathol 2007;15:11–36.
33. BlitzerA, BrinMF. The dystonic larynx. J Voice 1992;6:294–7.
34. AronsonA. Clincial Voice Disorders: An Interdisciplinary Approach. New York: Thieme-Stratton, 1990.
35. AdamsSG, DykstraA. Hypokinetic dysarthria. In McNeilMR, ed. Clinical Management of Sensorimotor Speech Disorders, 2nd edition. New York: Thieme, 2009;166–86.
36. KemplerD, Van LanckerD. Effect of speech task on intelligibility in dysarthria: a case study of Parkinson’s disease. Brain Lang 2002;80:449–64.
37. KentRD, KimY. The assessment of intelligibility in motor speech disorders. In LowitA, KentRD, eds. Assessment of Motor Speech Disorders. San Diego: Plural Publishing, 2011;21–37.
38. TjadenK, WildingGE. Rate and loudness manipulations in dysarthria: acoustic and perceptual findings. J Speech Lang Hear Res 2004;47:766–83.
39. YorkstonKM, BeukelmanDR. Assessment of Intelligibility of Dysarthric Speech. Austin: Pro-Ed, 1983.
40. ZraickRI, DavenportDJ, TabbalSD, et al. Reliability of speech intelligibility ratings using the Unified Huntington’s Disease Rating Scale. J Med Speech Lang Pathol 2004;12:31–40.
41. ForrestK, WeismerG. Acoustic analysis of motor speech disorders. In McNeilMR, ed. Clinical Management of Sensorimotor Speech Disorders, 2nd edition. New York: Thieme, 2009;46–63.
42. MurdochBE. Physiological assessment. In LowitA, KentRD, eds. Assessment of Motor Speech Disorders. San Diego: Plural Publishing, 2011;39–74.
43. DickinsonS, BarbourRS, BradyM, ClarkAM, PatonG. Patients’ experiences of disruptions associated with post-stroke dysarthria. Int J Lang Commun Disord 2008;43:135–53.
44. HarteliusL, ElmbergM, HolmR, LövbergA, NikolaidisS. Living with dysarthria: evaluation of a self-report questionnaire. Folia Phoniatr Logo 2008;60:11–19.
45. WalsheM, MillerN. Living with acquired dysarthria: the speaker’s perspective. Disabil Rehabil 2012;33:195–203.
46. WalsheM. The psychosocial impact of acquired motor speech disorders. In LowitA, KentRD, eds. Assessment of Motor Speech Disorders. San Diego: Plural Publishing, 2011;97–122.
47. WalsheM, PeachR, MillerN. The dysarthria impact profile: Validation of an instrument to measure psychosocial impact in dysarthria. Int J Lang Commun Disord 2009;44:693–715.
48. RamigLO, SapirS, CountrymanS, et al. Intensive voice treatment (LSVT) for patients with Parkinson’s disease: a 2 year follow up. J Neurol Neurosurg Psychiatry 2001;71:493–8.
49. Ofer-NoyN, DudaiY, KarniA. Skill learning in mirror reading: how repetition determines acquisition. Cog Brain Res 2003;17:507–21.
50. KleimJA, JonesTA. Principles of experience-dependent neural plasticity: implications for rehabilitation after brain damage. J Speech Lang Hear Res 2008;51:S225–39.
51. BaumgartnerCA, SapirS, RamigLO. Voice quality changes following phonatory-respiratory effort treatment (LSVT) versus respiratory effort treatment for individuals with Parkinson disease. J Voice 2001:15:105–14.
52. SmithM, RamigLO, DromeyC, PerezK, SamandariR. Intensive voice treatment in Parkinson’s disease: Laryngostroboscopic findings. J Voice 1995;9:453–9.
53. SapirS, SpielmanJ, RamigL, StoryB, FoxC. Effects of intensive voice treatment (LSVT®) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings. J Speech Hear Res 2007;50:889–912.
54. SpielmanJ, BorodJ, Ramig, L. The effects of intensive voice treatment on facial expressiveness in Parkinson disease: preliminary data. Cognit Behav Neurol 2003;16:177–88.
55. El-SharkawiA, RamigL, LogemannJA, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT®): a pilot study. J Neurol Neurosurg Psychiatry 2002;72:31–6.
56. LiottiM, RamigLO, VogelD, et al. Hypophonia in Parkinson’s disease: neural correlates of voice treatment revealed by PET. Neurology 2003;60:432–40.
57. NarayanaS, FoxPT, ZhangW, et al. Neural correlates of efficacy of voice therapy in Parkinson’s disease identified by performance-correlation analysis. Hum Brain Mapp 2010;31:222–36.
58. ArmstrongL, JansD, MacDonaldA. Parkinson’s disease and aided AAC: some evidence from practice. Int J Lang Commun Disord 2000;35:377–89.
59. RubowR, SwiftE. A microcomputer-based wearable biofeedback device to improve transfer of treatment in parkinsonian dysarthria. J Speech Hear Disord 1985;50:178–85.
60. DagenaisPA, SouthwoodMH, LeeTL. Rate reduction methods for improving intelligibility of dysarthric speaker with Parkinson’s disease. J Med Speech-Lang Pathol 1998;6:143–57.
61. HelmN. Management of palilalia with a pacing board. J Speech Hear Disord 1979;44:350–3.
62. CroweE, EnderbyP. The effects of an alphabet chart on the speaking rate and intelligibility of speakers with dysarthria. In YorkstonKM, BeukelmanDR, eds. Recent Advances in Clinical Dysarthria. Boston: College-Hill, 1989;99–108.
63. DuffyJF. Managing the dysarthrias. In DuffyJR, ed. Motor Speech Disorders. Substrates, Differential Diagnosis, And Management. 2nd edition. St. Louis: Elsevier Mosby, 2005;465–505.
64. DworkinJP. Bite-block therapy for oromandibular dystonia. In CannitoMP, YorkstonKM, BeukelmanDR, eds. Neuromotor Speech Disorders: Nature, Assessment, and Management. Baltimore: Brookes Publishing, 1998.
65. HaddadMS, CummingsJL. Huntington’s disease. Psychiat Clin N Am. 1997;20:359–64.
66. StocchiF, BrusaL. Cognition and emotion in different stages and subtypes of Parkinson’s disease. J Neurol 2000;247:114–21.
67. ArslandD, ZaccaiJ, BrayneC. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 2005;20:1255–63.
68. EmreM. Dementia associated with Parkinson’s disease. Lancet Neurol 2003;2:229–37.
69. GoldmanW, BatyJ, BucklesV, SahrmannS, MorrisJ. Cognitive and motor functioning in Parkinson’s disease. Arch Neurology 1998;55:674–80.
70. VerbaanD, MarinusJ, VisserM, et al. Cognitive impairment in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2007;78:1182–7.
71. PaulsenJS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep 2011;11:474–83.
72. HancockA, LaPointeL, Whelan, B-M. Cognitive–linguistic disorder in Parkinson disease. In TheodorosD, RamigL, eds. Communication and Swallowing in Parkinson Disease. San Diego: Plural Publishing, 2011;123–78.
73. EngleRW, ConwayARA. Working memory and comprehension. In LogieRH, GilhoolyKJ, eds. Working Memory and Thinking. Abingdon: Psychology Press, 1998; 66–90.
74. GrossmanM, CarvelS, SternMB, GollompS, HurtigH. Sentence comprehension in Parkinson’s disease: the role of attention and memory. Brain Lang 1992;42:347–84.
75. VerledenS, VingerhoetsG, SantensP. Heterogeneity of cognitive dysfunction in Parkinson’s disease. Eur Neurol 2006;58:34–40.
76. CheneryHJ, CoplandDA, MurdochBE. Complex language function and subcortical mechanisms: evidence from Huntington’s disease and patients with nonthalamic subcortical lesions. Int J Lang Commun Disord 2002;37:459–74.
77. LewisFM, LaPointeLL, MurdochBE, CheneryHJ. Language impairment in Parkinson’s disease. Aphasiology. 1998;12:193–206.
78. ZgaljardicDJ, BorodJC, FoldiNS, MattisP. A review of the cognitive and behavioral sequelae of Parkinson’s disease: relationship to frontostriatal circuitry. Cognit Behav Neurol 2003;16:193–210.
79. AngwinA, CoplandDA, CheneryH, MurdochB, SilburnP. The influence of dopamine on semantic activation in Parkinson’s disease: evidence from a multipriming task. Neuropsychology 2006;20:299–306.
80. CaplanD, WatersGS. Verbal working memory and sentence comprehension. Behav Brain Sci 1999;22:77–126.
81. IllesJ, MetterEJ, HansonWR, IritaniS. Language production in Parkinson’s disease: acoustic and linguistic considerations. Brain Lang 1988;33:146–60.
82. LeeC, GrossmanM, MorrisJ, SternMB, HurtigH. Attentional resource and processing speed limitations during sentence processing in Parkinson’s disease. Brain Lang 2003;85:347–56.
83. HarteliusL, JonssonM, RickebergA, Laakso, K. Communication and Huntington’s disease: qualitative interviews and focus groups with persons with Huntington’s disease, family members, and carers. Int J Lang Commun Disord 2010;45:381–93.
84. SaldertC, ForsA, StröbergS, HarteliusL. Comprehension of complex discourse in different stages of Huntington’s disease. Int J Lang Comm Disord 2010;45:656–69.
85. RohrerD, SalmonDP, WixtedJT, PaulsenJS. The disparate effects of Alzheimer’s disease and Huntington’s disease on semantic memory. Neuropsychology 1999;13:381–8.
86. WhelanB-M. Assessment and treatment of cognitive–linguistic disorder in Parkinson disease. In TheodorosD, RamigL, eds. Communication and Swallowing in Parkinson Disease. San Diego: Plural Publishing, 2011;179–98.
87. SpreenO, BentonAL. Neurosensory Centre Comprehensive Examination for Aphasia. Victoria: University of Victoria, 1977.
88. KerteszA. Western Aphasia Battery – Revised. New York: Pearson, 2006.
89. KaplanE, GoodglassH, WeintraubS. Boston Naming Test. Philadelphia: Lippincott Williams and Wilkins, 1983.
90. WiigEH, SecordW. Test of Language Competence – Expanded Edition. New York: The Psychological Corporation, 1989.
91. HuisinghR, BarrettM, ZachmanL, BlagdenC, OrmanJ. The Word Test – Revised: A Test of Expressive Vocabulary and Semantics. Illinois: Linguisystems, 1990.
92. WiigEH, SemelE. Development of comprehension of logical grammatical sentences by grade school children. Percept Motor Skill 1974;38:171–6.
93. HinchliffeFJ, MurdochBE, TheodorosDG. Treatment of cognitive–linguistic communication disorders following traumatic brain injury. In MurdochBE, TheodorosDG, eds. Traumatic Brain Injury: Associated Speech, Language and Swallowing Disorders. San Diego: Singular Publishing, 2001;273–309.
94. FrattaliCM, ThompsonD, HollandA, WohlC, FerketicM. American Speech Language and Hearing Association Functional Assessment of Communication Skills for Adults. Rockville: ASHA, 1995.
95. DonovanN, VelozoCA, RosenbekJ. The Communicative Effectiveness Survey: investigating its item level psychometric properties. J Med Speech Lang Pathol 2007;15:433–77.
96. HollandA, FrattaliCM, FrommB. Communication Activities of Daily Living (CADL-2). Austin: Pro-Ed, 1998.
97. WirzSL, SkinnerC, DeanE. Revised Edinburgh Functional Communication Profile. Arizona: Communication Skill Builders, 1990.
98. CiucciM, Mahler, L, McFarlandDH. Swallowing disorders in Parkinson disease. In TheodorosD, RamigL, eds. Communication and Swallowing in Parkinson Disease. San Diego: Plural Publishing, 2011;199–223.
99. RosenbekJC, JonesH. Dysphagia in Movement Disorders. San Diego: Plural Publishing, 2009.
100. MillerN, AllcockL, HildrethAJ, et al. Swallowing problems in Parkinson disease: frequency and clinical correlates. J Neurol Neurosurg Psychiatry 2009;80:1047–9.
101. MonteFS, da Silva-JuniorFP, Braga-NetoP, Nobre e SouzaMA, de BruinVM. Swallowing abnormalities and dyskinesia in Parkinson’s disease. Mov Disord 2005;20:457–62.
102. PotulskaA, FriedmanA, KrolickiL, SpychalaA. Swallowing disorders in Parkinson’s disease. Parkinsonism Relat Disorder 2003;9:349–53.
103. TrocheMS, SapienzaCM, RosenbekJC. Effects of bolus consistency on timing and safety of swallow in patients with Parkinson’s disease. Dysphagia 2008;23:26–32.
104. ManciniF, ZangagliaR, CristinaS, et al. Double-blind placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in Parkinsonism. Mov Disord 2003;18:685–8.
105. NagayaM, KachiT, YamadaT, IgataA. Videofluorographic study of swallowing in Parkinson’s disease. Dysphagia 1998;13:95–100.
106. DavenportP. Urge-to-cough: what can it teach us about cough?Lung 2008;86:S107–11.
107. PittsT, BolserD, RosenbekJ, TrocheM, SapienzaC. Voluntary cough production and swallow dysfunction in Parkinson’s disease. Dysphagia 2008;23:297–301.
108. RobbinsJA, LogemannJA, KirshnerHS. Swallowing and speech production in Parkinson’s disease. Ann Neurolol 1986;19:283–7.
109. ChouKL, EvattM, HinsonV, KompolitiK. Sialorrhea in Parkinson’s disease: a review. Mov Disord 2007;22:2306–13.
110. KalfJG, SmitAM, BloemBR, et al. Botulinum toxin A for drooling in Parkinson’s disease: a pilot study to compare submandibular to parotid gland injections. Parkinsonism Related Disord 2007;13:532–4.
111. TumilasciOR, CersosimoMG, BelforteJE, et al. Quantitative study of salivary secretion in Parkinson’s disease. Mov Disord 2006;21:660–7.
112. EadieMJ, TyrerJH. Alimentary disorder in parkinsonism. 1965;14:13–22.
113. HeemskerkA-W, RoosRAC. Dysphagia in Huntington’s disease: a review. Dysphagia 2011;26:62–6.
114. HamakawaS, KodaC, UmenoH, et al. Oropharyngeal dysphagia in a case of Huntington’s disease. Auris Nasus Larynx 2004;31:171–6.
115. KagelMC, LeopoldNA. Dysphagia in Huntington’s disease: a 16-year retrospective study. Dysphagia 1992;7:106–14.
116. LeopoldNA, KagelMC. Dysphagia in Huntington’s disease. Arch Neurol 1985;42:57–60.
117. LogemannJ. A.Evaluation and Treatment of Swallowing Disorders, 2nd edn. Austin: Pro-Ed, 1998.
118. LogemannJA, GenslerG, RobbinsJ, et al. A randomized study of three interventions for aspiration of thin liquids in patients with dementia or Parkinson’s disease. J Speech Lang Hear Res 2008;51:173–83.
119. RobbinsJ, GangnonRE, TheisST, et al. The effects of lingual exercise on swallowing in older adults. J Am Geriatric Soc 2005;53:1483–9.
120. PittsT, BolserD, RosenbekJ, et al. Impact of expiratory muscle strength training on voluntary cough and swallow function in Parkinson’s disease. Chest 2009;135:1301–8.
121. LogemannJA, BoshesB, FisherHB. The steps in the degeneration of speech and voice control in Parkinson’s disease. In SiegfriedJ, ed. Parkinson’s Disease: Rigidity, Akinesia, Behavior. Vienna: Hans Huber, 1973;101–12.
122. LagallaG, MillevolteM, CapecciM, ProvincialiL, CeravoloMG. Botulinum toxin type A for drooling in Parkinson’s disease: a double-bind, randomized, placebo-controlled study. Mov Disord 2006;21:704–7.
123. MarksL, TurnerK, O’SullivanJ, DeightonB, LeesA. Drooling in Parkinson’s disease: a novel speech and language therapy intervention. Int J Lang Commun Disord 2001;36:S282–7.
124. MorrisJ, MuellerJ, JonesM. Tomorrow’s elders with disabilities: what the wireless industry needs to know. J Eng Design 2010;21:131–46.
125. TheodorosD. A new era in speech-language pathology practice: innovation and diversification. Int J Speech Lang Pathol 2012;14: 189–90.
126. ConstantinescuG, TheodorosDG, RussellT, et al. Assessing disordered speech and voice in Parkinson’s disease: a telerehabilitation application. Int J Lang Commun Disord 2010;45:630–44.
127. SharmaS, WardEC, RussellT, TheodorosDG. Assessing swallowing disorders online: a pilot telerehabilitation study. Telemed e-Health 2011;17:688–95.
128. ConstantinescuG, TheodorosDG, RussellT, et al. Treating disordered speech and voice in Parkinson’s disease online: a randomised controlled noninferiority trial. Int J Lang Commun Disord 2010;46:1–16.
129. HalpernA, MatosC, RamigL, PetskaJ, SpielmanJ. LSVTC – a PDA supported speech treatment for Parkinson’s disease. Paper presented at the 9th International Congress of Parkinson’s Disease and Movement Disorders, New Orleans, 2005.

References

1. MillerJ, NilssonD. Contemporary issues in health work. In ConnollyM and HarmsL, eds. Social Work Contexts and Practice, 2nd edition, South Melbourne: Oxford University Press, 2009;ch. 13.
2. SilvermanE. From ideological to competency based: the rebranding and maintaining of medical social work identity. Social Work 2008;53:89–91
3. Department of Health. Parkinson’s Disease Services Model of Care. Perth: Aged Care Network, 2008.
4. MorrisM, IansekR, eds. Parkinson’s Disease: A Team Approach. Cheltenham, Australia: Southern Heath Care Network, 1997.
5. Australian Government Productivity Commission. Caring for Older Australians: Overview, Report No. 53, Final Inquiry Report. Canberra: Australian Government Productivity Commission, 2011. See: http://www.pc.gov.au/projects/inquiry/aged-care [accessed 10.04.12].
6. VeenhuizenRB, KoostraB, VinkW, et al. Coordinated multidisciplinary care for ambulatory Huntington’s disease patients. Evaluation of 18 months of implementation. Orphanet J Rare Disord 2011;6:77.
7. GehlertS, BrowneTA, eds. Handbook for Health Social Work. Hoboken: Wiley, 2006.
8. JohnsonJL, GrantG. Medical Social Work. Boston: Pearson Education, 2005.
9. MattainiMA, LoweryCT, MeyerCH, eds. The Foundations of Social Work Practice: A Graduate Text. Washington: NASW Press, 1998.
10. MonahanDJ. HookerK. Caregiving and social support in two illness groups. Social Work 1997;42:278–87.
11. EricksonCLMuramatsuNParkinson’s disease, depression and medication adherence. J Gerontol Social Work, 2004;42: 3–18.